title: Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate.
abstract: Macrophage scavenger receptor (MSR)-positive inflammatory cells and tumor-associated macrophages (TAMs) have been reported to regulate the growth of various cancers. In this study, the infiltration of MSR-positive cells and TAMs was analyzed to predict the outcome of repeat biopsy in men diagnosed as having no malignancy at the first prostate biopsy. Repeat biopsy of the prostate was carried out in 92 patients who were diagnosed as having no malignancy at the first biopsy. Of these, 30 patients (32.6%) were positive for prostate cancer at the repeat biopsy. Tumor-associated macrophages and MSR-positive cells were immunohistochemically stained with mAbs CD68 and CD204, respectively. Six ocular measuring fields were chosen randomly under a microscope at x400 power in the initial negative biopsy specimens, and the mean TAM and MSR counts for each case were determined. No difference in TAM count was found between the cases with or without prostate cancer. By contrast, the MSR count in patients with cancer was significantly lower than that in patients without cancer at the repeat biopsy (P < 0.001). Logistic regression analysis indicated that the MSR count at first biopsy is a significantly better predictive factor for positive repeat biopsy than PSA velocity, interval between first and repeat biopsies, or TAM count. Decreased infiltration of MSR-positive cells in negative first biopsy specimens was correlated with positive findings in the repeat biopsy. The MSR count might be a good indicator for avoiding unnecessary repeat biopsies.
authors.affiliation: Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. nono@uro.med.osaka-u.ac.jp
authors.forename: Norio
authors.initials: N
authors.lastname: Nonomura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takayama
authors.forename: Atsunari
authors.initials: A
authors.lastname: Kawashima
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Mukai
authors.forename: Akira
authors.initials: A
authors.lastname: Nagahara
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nakai
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakayama
authors.forename: Akira
authors.initials: A
authors.lastname: Tsujimura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Nishimura
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Aozasa
authors.forename: Akihiko
authors.initials: A
authors.lastname: Okuyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D051117:Scavenger Receptors, Class A / Q000032:analysis / Q000502:physiology*; D012680:Sensitivity and Specificity
chemical_list: C495139:MSR1 protein, human; D051117:Scavenger Receptors, Class A; D017430:Prostate-Specific Antigen
references.citation: Exp Mol Pathol. 2004 Oct;77(2):153-9
references.pmid: 15351240
references.citation: Urology. 2002 Nov;60(5):836-40
references.pmid: 12429311
references.citation: Carcinogenesis. 2005 Jul;26(7):1170-81
references.pmid: 15498784
references.citation: J Biol Chem. 1998 Jan 16;273(3):1562-7
references.pmid: 9430696
references.citation: Cancer. 2008 Dec 1;113(11):3075-99
references.pmid: 18823041
references.citation: J Natl Cancer Inst. 1998 Nov 4;90(21):1648-53
references.pmid: 9811314
references.citation: Eur Urol. 2007 Sep;52(3):639-41
references.pmid: 17451871
references.citation: J Urol. 1994 Nov;152(5 Pt 1):1358-68
references.pmid: 7523702
references.citation: J Urol. 2000 Mar;163(3):813-8
references.pmid: 10687983
references.citation: Clin Radiol. 2006 Feb;61(2):142-53
references.pmid: 16439219
references.citation: Urol Oncol. 2007 May-Jun;25(3):250-9
references.pmid: 17483024
references.citation: J Cancer Res Clin Oncol. 2004 Apr;130(4):217-21
references.pmid: 14749923
references.citation: Nat Rev Cancer. 2007 Apr;7(4):256-69
references.pmid: 17384581
references.citation: J Pathol. 2008 Sep;216(1):15-24
references.pmid: 18553315
references.citation: Eur J Cancer. 2006 Apr;42(6):717-27
references.pmid: 16520032
references.citation: Pathol Int. 2009 May;59(5):300-5
references.pmid: 19432671
references.citation: Prostate. 1998 Sep 15;37(1):19-29
references.pmid: 9721065
references.citation: Eur Urol. 2008 Nov;54(5):1081-8
references.pmid: 18602209
references.citation: BJU Int. 2007 Oct;100(4):733-7
references.pmid: 17662075
references.citation: J Urol. 2008 Jul;180(1):146-9
references.pmid: 18485383
references.citation: Semin Cancer Biol. 1991 Jun;2(3):189-95
references.pmid: 1912527
references.citation: Nature. 2002 Dec 19-26;420(6917):860-7
references.pmid: 12490959
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Urology. 2007 Mar;69(3):532-5
references.pmid: 17382159
references.citation: J Urol. 2000 Apr;163(4):1144-8; discussion 1148-9
references.pmid: 10737484
references.citation: Clin Cancer Res. 2003 Jul;9(7):2673-7
references.pmid: 12855646
references.citation: BJU Int. 2009 Feb;103(4):470-4
references.pmid: 18778349
references.citation: J Urol. 2003 Oct;170(4 Pt 1):1184-8; discussion 1188
references.pmid: 14501721
references.citation: Nat Genet. 2002 Oct;32(2):321-5
references.pmid: 12244320
references.citation: Urology. 2000 Apr;55(4):553-9
references.pmid: 10736500
references.citation: Cancer Res. 2000 Oct 15;60(20):5857-61
references.pmid: 11059783
references.citation: Am J Hum Genet. 2003 Jan;72(1):208-12
references.pmid: 12471593
references.citation: Cancer Res. 2004 Mar 15;64(6):2076-82
references.pmid: 15026346